Healthpeak Properties (DOC) Hisse Özeti
Healthpeak Properties, Inc. tam entegre bir gayrimenkul yatırım ortaklığı (GYO) ve S&P 500 şirketidir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 1/6 |
| Finansal Sağlık | 1/6 |
| Temettüler | 4/6 |
DOC Community Fair Values
Create NarrativeSee what 51 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Healthpeak Properties, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$22.06 |
| 52 Haftanın En Yüksek Seviyesi | US$22.95 |
| 52 Haftanın En Düşük Seviyesi | US$15.70 |
| Beta | 1 |
| 1 Aylık Değişim | 3.08% |
| 3 Aylık Değişim | 34.35% |
| 1 Yıllık Değişim | 30.22% |
| 3 Yıllık Değişim | 2.51% |
| 5 Yıllık Değişim | -40.95% |
| Halka arzdan bu yana değişim | 315.25% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 24
DOC: Brookfield Venture And Index Additions Will Support Future Upside
Analysts have raised their price target on Healthpeak Properties to $27.22 from $26.94. This change reflects revised assumptions about fair value, discount rate, revenue growth, profit margins, and future P/E levels.Anlatı Güncellemesi • Jul 10
DOC: Index Additions And Higher Earnings Outlook Will Support Future Upside
Analysts have raised their price target for Healthpeak Properties from $25.80 to $26.94, citing updated assumptions around revenue growth, profit margins, discount rates, and future P/E expectations. What’s in the News for Healthpeak Properties Healthpeak Properties, Inc.Recent updates
Anlatı Güncellemesi • Jul 24
DOC: Brookfield Venture And Index Additions Will Support Future Upside
Analysts have raised their price target on Healthpeak Properties to $27.22 from $26.94. This change reflects revised assumptions about fair value, discount rate, revenue growth, profit margins, and future P/E levels.Anlatı Güncellemesi • Jul 10
DOC: Index Additions And Higher Earnings Outlook Will Support Future Upside
Analysts have raised their price target for Healthpeak Properties from $25.80 to $26.94, citing updated assumptions around revenue growth, profit margins, discount rates, and future P/E expectations. What’s in the News for Healthpeak Properties Healthpeak Properties, Inc.
Anlatı Güncellemesi • Jun 26
DOC: Buybacks And Raised Earnings Guidance Will Support Measured Future Upside Potential
Analysts have slightly increased their price target on Healthpeak Properties to $21.44 from $20.83, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E levels. What's in the News for Healthpeak Properties Healthpeak Properties reported a share repurchase activity from January 1, 2026 to May 5, 2026, buying back 5,950,000 shares for US$100 million, representing 0.86% of its shares, according to a buyback tranche update.Seeking Alpha • Jun 19
Healthpeak Properties: This 6% Yielding REIT Has More Room To Run
Summary Healthpeak Properties remains a Strong Buy, combining value, income, and recovery potential in healthcare real estate. DOC’s outpatient medical and life sciences segments show improving occupancy, strong lease spreads, and embedded rent escalators supporting steady growth. The Janus Living spin-off unlocks value in senior housing, with DOC retaining 82% ownership and benefiting from high segment growth. DOC offers a 6.2% yield, BBB+ balance sheet, and trades at 11.2x forward P/FFO, well below its historical average. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jun 12
DOC: Raised 2026 Outlook And Buybacks Will Conceal Mounting Margin Risks
Analysts have adjusted their price target on Healthpeak Properties from $16.00 to $17.00, tying the change to updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Healthpeak Properties reported first quarter 2026 funds from operations as adjusted (FFOA) of $0.45 per share, which was above analyst estimates, supported by steady leasing momentum.Anlatı Güncellemesi • May 29
DOC: Buybacks And Higher Earnings Guidance Will Support Measured Future Upside Potential
Analysts have nudged their price target for Healthpeak Properties from about $20.17 to roughly $20.83, reflecting updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Healthpeak Properties reported repurchasing 5,950,000 shares for US$100 million between January 1, 2026 and May 5, 2026, representing 0.86% of its shares under the ongoing buyback program announced on July 25, 2024 (Key Developments).Anlatı Güncellemesi • May 13
DOC: Buyback Activity And Raised Earnings Outlook Will Mask Weaker Margin Outlook
Analysts have kept their $16.00 price target on Healthpeak Properties unchanged, citing updated assumptions that include a slightly higher discount rate, a shift to declining revenue growth, lower profit margins, and a much higher future P/E estimate. What's in the News From January 1, 2026 to May 5, 2026, Healthpeak Properties repurchased 5,950,000 shares, representing 0.86% of its stock for US$100 million under its existing buyback program (Key Developments).Anlatı Güncellemesi • Apr 28
DOC: Higher Margins And Earnings Outlook Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties by about $0.64 to $25.80 as updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E are incorporated into their models. What's in the News Healthpeak Properties reported that from October 1, 2025 to December 31, 2025, it repurchased 0 shares for $0 million under its existing buyback program, closing out a total repurchase of 5,091,156 shares, or 0.73%, for $94.17 million under the authorization announced on July 25, 2024 (Key Developments).Anlatı Güncellemesi • Apr 14
DOC: Share Repurchases And Improved Margins Will Support Future Upside Potential
Analysts have slightly raised their price target on Healthpeak Properties to about $26.44, a marginal change from roughly $26.43. The revision reflects updated assumptions related to discount rate, revenue growth, profit margin and a projected future P/E near 98x.Anlatı Güncellemesi • Mar 31
DOC: Earnings Guidance And Completed Buyback Will Shape Measured Future Return Potential
Analysts now hold their $16.00 price target on Healthpeak Properties while adjusting underlying assumptions slightly on discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning rather than a major shift in their view of the stock.Anlatı Güncellemesi • Mar 16
DOC: Share Repurchases And Stronger Margins Will Support Future Upside Potential
Analysts now estimate Healthpeak Properties' fair value price target at about $26.43, compared with the previous estimate of roughly $26.71. The revision reflects updated views on revenue growth, profit margin and future P/E assumptions.Anlatı Güncellemesi • Mar 02
DOC: Earnings Outlook And Completed Buyback Will Highlight Limited Future Upside
Analysts have maintained their $16.00 price target for Healthpeak Properties. They cite only small adjustments to assumptions around discount rate, revenue growth, profit margin, and future P/E that together do not materially change their view of the stock’s valuation.Anlatı Güncellemesi • Feb 16
DOC: Share Buyback Completion And Earnings Outlook Will Shape Fair Prospects
Analysts have adjusted their price target on Healthpeak Properties from $18.00 to $16.00. The revision reflects updated models that incorporate a slightly higher discount rate, a lower profit margin assumption and a revised future P/E estimate, while also taking into account a higher revenue growth outlook.Anlatı Güncellemesi • Feb 02
DOC: Stable Margins And Modest Assumption Shifts Will Support Future Upside Potential
Analysts now estimate fair value for Healthpeak Properties at about US$20.17 per share, compared with roughly US$20.68 previously. The change reflects slightly revised assumptions around discount rates, long term revenue growth, profit margins and future P/E levels.Anlatı Güncellemesi • Jan 19
DOC: Share Repurchases And Higher Future P/E Will Support Upside Potential
Analysts have nudged their price target on Healthpeak Properties slightly higher to about US$26.71 from roughly US$26.65, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. Together, these factors shape a modestly revised outlook for the shares.Anlatı Güncellemesi • Jan 05
DOC: Completed Buyback And Stable Margins Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties to about US$20.68 per share from roughly US$20.92, citing slightly higher discount rate assumptions along with modest adjustments to revenue growth, profit margin, and future P/E inputs in their models. What's in the News From July 1, 2025 to September 30, 2025, Healthpeak Properties reported no share repurchases under its current program, with 0 shares bought for US$0 million in that period (Key Developments).Anlatı Güncellemesi • Dec 14
DOC: Share Repurchases And Margin Outlook Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties to approximately $26.65 from about $27.73, reflecting slightly higher discount-rate assumptions and more modest revenue growth expectations, partially offset by improved profit margin and a lower projected future price to earnings multiple. What's in the News Completed repurchase of 5,091,156 shares for approximately $94.17 million under the buyback program announced on July 25, 2024, representing about 0.73% of shares (Key Developments) No additional shares were repurchased between July 1, 2025 and September 30, 2025 under the existing buyback tranche, with total spending of $0 million in the period (Key Developments) Removed from the FTSE All-World Index (USD), which may affect index-linked ownership and trading volumes for the stock (Key Developments) Valuation Changes Fair Value Estimate decreased slightly to approximately $26.65 from about $27.73.Anlatı Güncellemesi • Nov 30
DOC: Lower Discount Rate Will Support Improving Profit Margins Moving Forward
Analysts have modestly increased their price target for Healthpeak Properties from $20.86 to $20.92. This reflects slightly improved forward-looking profit margins and a lower discount rate, although it is partially tempered by a more conservative outlook for revenue growth.Anlatı Güncellemesi • Nov 16
DOC: Discount Rate Improvements Will Drive Margin Gains Ahead
Analysts have slightly lowered their price target for Healthpeak Properties from $21.03 to $20.86. They cite modest adjustments in growth and discount rate assumptions, while also noting a marginal improvement in profit margins.Anlatı Güncellemesi • Nov 01
DOC: Share Repurchase And Index Removal Will Unlock Future Upside Potential
Analysts have slightly lowered their price target for Healthpeak Properties to $21.03 from $21.19, citing modest reductions in revenue growth and profit margin expectations as key factors behind the revision. What's in the News Healthpeak Properties completed the repurchase of 5,091,156 shares, representing 0.73% of outstanding shares, for $94.17 million under its buyback announced on July 25, 2024 (Key Developments).Anlatı Güncellemesi • Oct 17
Outpatient And Life Science Trends Will Create Future Opportunities
Analysts have slightly lowered their price target for Healthpeak Properties from $21.31 to $21.19, citing a modest increase in expected discount rates and revenue growth, along with a small dip in projected profit margin. What's in the News Healthpeak Properties, Inc.Anlatı Güncellemesi • Oct 03
Outpatient And Life Science Trends Will Create Future Opportunities
Analysts have slightly revised their price target for Healthpeak Properties downward from $21.38 to $21.31. This change reflects minor updates to discount rate and valuation assumptions.Anlatı Güncellemesi • Sep 17
Outpatient And Life Science Trends Will Create Future Opportunities
Healthpeak Properties' fair value estimate edged only slightly lower as both its future P/E ratio and net profit margin saw negligible declines, resulting in a marginal decrease in the consensus analyst price target from $21.53 to $21.38. What's in the News Lowered full-year 2025 diluted EPS guidance to $0.25–$0.31 from $0.30–$0.36.Anlatı Güncellemesi • Sep 02
Outpatient And Life Science Trends Will Create Future Opportunities
The slight reduction in Healthpeak Properties’ future P/E ratio suggests a modestly improved earnings outlook relative to price, but with consensus revenue growth unchanged, analysts have only marginally decreased the fair value estimate from $21.72 to $21.53. What's in the News Healthpeak Properties lowered its full-year 2025 diluted EPS guidance to $0.25 – $0.31 from $0.30 – $0.36.Anlatı Güncellemesi • Aug 19
Outpatient And Life Science Trends Will Create Future Opportunities
Healthpeak Properties’ fair value saw a marginal decrease as a slight drop in its future P/E multiple reflected modestly softer forward expectations. What's in the News Completed share repurchase program, buying 5,091,156 shares (0.73%) for $94.17 million.Seeking Alpha • Apr 10
Healthpeak Properties: Defensive REIT With Strong Dividend And Post-Merger Upside
Summary Healthpeak Properties is a high-quality healthcare REIT trading at a low valuation, offering 25-30% price appreciation and a ~6.7% annual dividend yield. The successful merger with Physicians Realty Trust has created a dominant healthcare REIT with significant synergies, improving operational performance and tenant diversification. Healthpeak's portfolio benefits from a strong demographic tailwind, robust leasing activity, and strategic focus on outpatient medical buildings and life science properties. Trading at a lower valuation than peers, Healthpeak's strong fundamentals make it an attractive buy for total return and income-focused investors. Read the full article on Seeking AlphaSeeking Alpha • Mar 13
Why Healthpeak Is A Smart Buy For Income Investors
Summary Healthpeak Properties offers a compelling investment opportunity with a 5.9% dividend yield, strong operating fundamentals, and an attractive valuation. DOC's diversified healthcare portfolio benefits from limited new supply, robust demand, and strategic loan investments in life sciences for immediate earnings accretion. With a strong balance sheet and a forward P/FFO of 11.2, DOC is well-positioned for long-term growth and potential market-beating returns. Read the full article on Seeking AlphaSeeking Alpha • Jan 06
A REIT Geek Who Likes Healthpeak
Summary Healthpeak Properties is a top healthcare REIT with a robust portfolio, strong fundamentals, and a well-covered 6% yield, making it an attractive investment. Despite recent price declines, Healthpeak's AFFO growth, low leverage, and strategic life-science assets position it for stability and modest growth. The lab space market's tightening supply and increased biotech capital raise Healthpeak's valuation potential, justifying a conservative P/AFFO of 14-16x. At a share price of $16-$18, Healthpeak offers a compelling buy opportunity with an expected annualized return of 16-17%, supported by analyst consensus. Read the full article on Seeking AlphaSeeking Alpha • Dec 22
Healthpeak Properties: I'm Buying The 6% Dividend Yield
Summary Healthpeak Properties has dipped and now offers a 6% dividend yield that's 147% covered by its fiscal 2024 third-quarter FFO. The REIT generated free cash flow in excess of dividend payments during the third quarter. Spiking US 10-year Treasury yield forms a material headwind for stock price growth. Read the full article on Seeking AlphaSeeking Alpha • Oct 21
Healthpeak: Potential Upside Still Exists, But Don't Expect Much
Summary Healthpeak Properties is a BBB+ rated healthcare REIT with a solid portfolio, low leverage, and a well-covered 5.4% yield, offering a conservative 15% annualized return. The company is nearing full valuation but remains attractive due to its stable fundamentals, slight growth prospects, and recent merger benefits. Despite low growth estimates, Healthpeak's conservative P/AFFO of 14.25x suggests a potential upside, making it a "Buy" with a $27/share price target. Healthpeak fulfills all my investment criteria except being cheap, making it a sound investment for conservative, double-digit returns. Read the full article on Seeking Alpha
Yeni Anlatı • Aug 21
Strategic Mergers And Key Life Science Leases Propel Revenue And Earnings Growth
Execution of priorities like merger integration and asset sales directly boosts 2024 guidance, signaling positive revenue and earnings impact.Seeking Alpha • Jul 18
Healthpeak: Missing The Boat Above $20/Share
Summary I update on investment in Healthpeak REIT, owning a significant stake with a positive return on investment and yield of over 7%. I highlight the undervaluation of Healthpeak, positive outlook on a diverse portfolio, and caution on current share price above $20. I maintain my thesis on Healthpeak as an attractive buy with conservative double-digit upside potential, based on sound fundamentals and future growth prospects. Read the full article on Seeking AlphaSeeking Alpha • Jul 09
Healthpeak Properties: A 6.1% Yielding Healthcare Trust With Upside
Summary Healthpeak Properties is a leading U.S. real estate investment trust focused on medical office buildings, poised for long-term growth. The merger with Physician Realty Trust has increased the trust's portfolio to 748 properties, with potential for $80 million in synergies. With a steady dividend and strong funds from operations growth, Healthpeak Properties is a compelling investment for passive income investors. Read the full article on Seeking AlphaSeeking Alpha • May 14
Healthpeak Q1 - The "Best" In The Space With A 15% Upside
Summary Healthpeak (DOC) is an attractive healthcare REIT with a diverse portfolio and a yield of over 7%. The company is unlikely to see significant near-term AFFO growth, but offers stability and potential slight growth. The stock is currently undervalued and has a conservative double-digit upside, making it a good buy. Read the full article on Seeking AlphaHissedar Getirileri
| DOC | US Health Care REITs | US Pazar | |
|---|---|---|---|
| 7D | -0.09% | -0.4% | -2.6% |
| 1Y | 30.2% | 37.7% | 14.3% |
Getiri vs. Endüstri: DOC geçen yıl % 37.7 oranında getiri sağlayan US Health Care REITs sektörünün gerisinde kaldı.
Getiri vs Piyasa: DOC geçen yıl % 14.3 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| DOC volatility | |
|---|---|
| DOC Average Weekly Movement | 6.0% |
| Health Care REITs Industry Average Movement | 4.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: DOC son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: DOC 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1985 | 411 | Scott Brinker | www.healthpeak.com |
Healthpeak Properties, Inc., tam entegre bir gayrimenkul yatırım ortaklığı (REIT) ve S&P 500 şirketidir. Healthpeak, sağlık alanında araştırma ve hizmet sunumu için yüksek kaliteli gayrimenkullerin mülkiyetini elinde bulundurur, işletir ve geliştirir. Healthpeak Properties, Inc., Colorado eyaletinin Denver şehrinde bulunmaktadır.
Healthpeak Properties, Inc. Temel Bilgiler Özeti
| DOC temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$15.79b |
| Kazançlar(TTM) | US$221.63m |
| Gelir(TTM) | US$2.87b |
68.6x
F/K Oranı5.3x
P/S OranıDOC aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| DOC gelir tablosu (TTM) | |
|---|---|
| Gelir | US$2.87b |
| Gelir Maliyeti | US$1.20b |
| Brüt Kâr | US$1.68b |
| Diğer Giderler | US$1.45b |
| Kazançlar | US$221.63m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 04, 2026
| Hisse başına kazanç (EPS) | 0.32 |
| Brüt Marj | 58.33% |
| Net Kâr Marjı | 7.72% |
| Borç/Özkaynak Oranı | 115.0% |
DOC uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
5.5%
Mevcut Temettü Verimi68%
Ödeme OranıDOC güvenilir bir temettü ödüyor mu?
DOC temettü geçmişine ve kıyaslamalara bakın| Healthpeak Properties temettü tari̇hleri̇ | |
|---|---|
| Eski Temettü Tarihi | Jul 20 2026 |
| Temettü Ödeme Tarihi | Jul 31 2026 |
| Eski temettüye kadar geçen günler | 11 days |
| Temettü ödeme tarihine kadar geçen günler | 0 days |
DOC güvenilir bir temettü ödüyor mu?
DOC temettü geçmişine ve kıyaslamalara bakınŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/30 22:17 |
| Gün Sonu Hisse Fiyatı | 2026/07/30 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Healthpeak Properties, Inc. 37 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jacob Kilstein | Argus Research Company |
| David Rodgers | Baird |
| Adam Feinstein | Barclays |